此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation (REPACE)

2026年9月25日 更新者:Insel Gruppe AG, University Hospital Bern

Patient Selection and Long-Term Outcomes in Patients With a Pace & Ablate Strategy for Interventional Rate Control in Symptomatic Permanent Atrial Fibrillation - A Retrospective Multicenter Analysis

Atrioventricular node ablation with permanent pacing (the "pace-and-ablate" strategy) controls ventricular rate in atrial fibrillation that has not responded to drug therapy or catheter ablation. Chronic right ventricular pacing, however, can cause pacing-induced cardiomyopathy (PICM), and it is not well established which patients are at risk and should therefore receive conduction system pacing or biventricular pacing instead.

REPACE is a multicentre retrospective cohort of consecutive patients who underwent atrioventricular node ablation from January 2011 onwards at five centres in Switzerland, the United Kingdom and Poland: Liverpool Heart and Chest Hospital, Inselspital Bern, University Hospital Basel, Geneva University Hospitals and the Silesian Centre for Heart Diseases, Zabrze. More than 2,000 patients ablated up to March 2024 have been included to date; patients ablated after that date at the participating centres are being added.

The study has three aims: to validate, in an independent multicentre population, a previously published risk model for pacing-induced cardiomyopathy; to describe the procedural technique and outcomes of atrioventricular node ablation across different health systems; and to estimate the health-economic impact of the pace-and-ablate strategy.

Pacing-induced cardiomyopathy is defined as an absolute reduction in left ventricular ejection fraction of at least 10 percentage points to a value below 50%. All potential endpoints are adjudicated by a clinical events committee blinded to the classification made at the site.

研究概览

详细说明

Data collection. Baseline demographics, comorbidity, device and procedural data, electrocardiographic and echocardiographic measurements, follow-up events and mortality were abstracted from hospital records at each participating centre into a central electronic case report form.

Endpoint adjudication. Every potential endpoint is reviewed by two independent adjudicators blinded to the classification made at the site, with a third reviewer consulted where they disagree. Pacing-induced cardiomyopathy is assessed on every adjudicated event, independently of how that event is otherwise classified.

Analysis populations. The validation of the risk model is performed in the patients who had neither cardiac resynchronisation therapy nor conduction system pacing at baseline, because a decline in left ventricular function in an already resynchronised patient represents non-response to resynchronisation rather than pacing-induced cardiomyopathy. Patients with resynchronisation at baseline are described and contribute to the procedural and health-economic analyses. No lower limit of baseline ejection fraction is applied: since the definition requires a fall of at least 10 percentage points to a value below 50%, patients already below 50% at baseline can meet it.

Health-economic analysis. Direct costs are derived from Hospital Episode Statistics in the United Kingdom, individual procedure costs from the SwissEPnet registry for Switzerland, and diagnosis-related group and hospital costs for Switzerland and Poland, covering hospital charges, device costs and subsequent care for complications and follow-up. Cost-utility and cost-effectiveness analyses use Markov models to compare pacing strategies.

研究类型

观察性的

注册 (估计的)

2600

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Zabrze、波兰、41-800
        • 招聘中
        • Silesian Centre for Heart Diseases
        • 首席研究员:
          • Agnieszka Babińska, MD
      • Basel、瑞士、4031
        • 招聘中
        • University Hospital Basel
        • 首席研究员:
          • Christian Sticherling, MD
      • Geneva、瑞士、1205
        • 招聘中
        • Geneva University Hospitals
        • 首席研究员:
          • Haran Burri, MD
    • Canton of Bern
      • Bern、Canton of Bern、瑞士、3010
        • 招聘中
        • Inselspital, Universitätsspital Bern
        • 接触:
        • 首席研究员:
          • Nikola A Kozhuharov, PD Dr. med.
    • Merseyside
      • Liverpool、Merseyside、英国、L14 3PE
        • 招聘中
        • Liverpool Heart and Chest Hospital
        • 接触:
        • 首席研究员:
          • Dhiraj Gupta, MD, FRCP

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Consecutive adults with symptomatic atrial fibrillation refractory to drug therapy or catheter ablation who underwent atrioventricular node ablation as part of a pace-and-ablate strategy at five participating centres in Switzerland, the United Kingdom and Poland from January 2011 onwards.

Retrospective inclusion is covered by general consent to the further use of health-related data where this is on file. For deceased or uncontactable patients with no documented refusal, inclusion is covered by the exception from consent under Article 34 of the Swiss Human Research Act (Absence of informed consent), the project having been approved by the Kantonale Ethikkommission Bern. The United Kingdom site operates under IRAS 314643.

描述

Inclusion Criteria:

  • Age 18 years or older at the time of atrioventricular node ablation
  • Atrial fibrillation, undergoing atrioventricular node ablation with a permanent cardiac implantable electronic device already in situ or implanted as part of the pace-and-ablate strategy
  • Availability of baseline echocardiographic data, including left ventricular ejection fraction

Exclusion Criteria:

* Documented refusal of the further use of health-related data

Note: cardiac resynchronisation therapy or conduction system pacing at baseline is not an eligibility exclusion. Such patients are included in the cohort and in the procedural and health-economic analyses, but are excluded from the validation of the pacing-induced cardiomyopathy risk model, in which a decline in left ventricular function would represent non-response to resynchronisation. No lower limit of baseline ejection fraction is applied.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:RETROSPECTIVE

队列和干预

团体/队列
Pace-and-ablate cohort

Consecutive adults with atrial fibrillation who underwent atrioventricular node ablation with a permanent cardiac implantable electronic device at the five participating centres from January 2011 onwards. Within this cohort, the patients who had neither cardiac resynchronisation therapy nor conduction system pacing at baseline form the population for the validation of the pacing-induced cardiomyopathy risk model.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of pacing-induced cardiomyopathy (PICM)
大体时间:From atrioventricular node ablation up to 10 years

Proportion of patients who develop PICM, defined as an absolute reduction in left ventricular ejection fraction (LVEF) of at least 10 percentage points to a value below 50% on echocardiography after atrioventricular node ablation with ventricular pacing. Each potential event is adjudicated by two independent reviewers blinded to the classification made at the site, with a third reviewer consulted in case of disagreement.

From atrioventricular node ablation up to 10 years

次要结果测量

结果测量
措施说明
大体时间
All-cause mortality by pacing modality
大体时间:From atrioventricular node ablation up to 5 years

Proportion of patients who die from any cause, reported separately for right ventricular pacing, biventricular pacing and conduction system pacing.

From atrioventricular node ablation up to 5 years
Heart failure hospitalisation by pacing modality
大体时间:From atrioventricular node ablation up to 5 years

Proportion of patients with at least one hospitalisation for heart failure, reported separately for right ventricular pacing, biventricular pacing and conduction system pacing.

From atrioventricular node ablation up to 5 years
Acute procedural success of atrioventricular node ablation
大体时间:Periprocedural (index atrioventricular node ablation)

Proportion of procedures with complete atrioventricular block at the end of the procedure, i.e. intended loss of atrioventricular conduction with transition to ventricular pacing.

Periprocedural (index atrioventricular node ablation)
Use of a second ablation catheter, by type of first ablation catheter (irrigated versus non-irrigated)
大体时间:Periprocedural (index atrioventricular node ablation)

Proportion of procedures in which a second ablation catheter was required to achieve atrioventricular block, reported separately for procedures started with an irrigated and with a non-irrigated catheter.

Periprocedural (index atrioventricular node ablation)
Presence of a ventricular escape rhythm after atrioventricular node ablation
大体时间:Periprocedural (index atrioventricular node ablation)

Proportion of patients with a ventricular escape rhythm documented at the end of the atrioventricular node ablation procedure.

Periprocedural (index atrioventricular node ablation)
Procedure duration by use of a long sheath
大体时间:Periprocedural (index atrioventricular node ablation)

Duration of the atrioventricular node ablation procedure in minutes, reported separately for procedures performed with and without a long sheath.

Periprocedural (index atrioventricular node ablation)
Cumulative direct healthcare costs per patient
大体时间:From atrioventricular node ablation up to 5 years

Cumulative direct healthcare costs per patient in euros, covering the index procedure (hospital stay, device and consumables) and subsequent hospital care for complications and follow-up. Costs are derived from Hospital Episode Statistics (United Kingdom), the SwissEPnet registry and diagnosis-related group data (Switzerland, Poland) and converted to euros.

From atrioventricular node ablation up to 5 years
Incremental cost-effectiveness ratio of conduction system pacing versus right ventricular pacing
大体时间:From atrioventricular node ablation up to 5 years

Incremental cost per quality-adjusted life-year (QALY) gained, estimated with a Markov model from the observed event rates and direct healthcare costs, overall and across strata of predicted pacing-induced cardiomyopathy risk and of procedural complexity.

From atrioventricular node ablation up to 5 years
Return to sinus rhythm during follow-up
大体时间:From atrioventricular node ablation up to 5 years

Proportion of patients with documented return to sinus rhythm on electrocardiogram or device interrogation after atrioventricular node ablation.

From atrioventricular node ablation up to 5 years
Discrimination of the published and of an updated pacing-induced cardiomyopathy risk model (C-statistic)
大体时间:From atrioventricular node ablation up to 10 years

C-statistic (area under the receiver operating characteristic curve) for predicting pacing-induced cardiomyopathy, reported for the previously published risk model as originally specified and for a model updated in this cohort (recalibration and re-estimation of predictor weights, with candidate additional predictors), in patients without cardiac resynchronisation therapy or conduction system pacing at baseline.

From atrioventricular node ablation up to 10 years
Incremental cost-effectiveness ratio of biventricular pacing versus right ventricular pacing
大体时间:From atrioventricular node ablation up to 5 years

Incremental cost per quality-adjusted life-year (QALY) gained, estimated with a Markov model from the observed event rates and direct healthcare costs, overall and across strata of predicted pacing-induced cardiomyopathy risk and of procedural complexity.

From atrioventricular node ablation up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2011年1月5日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年9月8日

首先提交符合 QC 标准的

2026年9月25日

首次发布 (实际的)

2026年10月1日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月25日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2019-01151
  • 2019 (美国 NIH 拨款/合同)
  • 4079 (其他标识符:Insel Gruppe AG, University Hospital Bern)
  • 314643 (其他标识符:IRAS, UK Health Research Authority)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅